Hi teamIMO, thinking critically, I think it is far, far more...

Hi team

IMO, thinking critically, I think it is far, far more likely that the ann is concerning a big pharma takeover bid, instead of Incannex planning to acquire a smaller company. Biotechs rarely acquire smaller companies especially when they run so lean and prioritise clinical progression of existing assets. Doubly so when said assets are as high-potential as the ones IHL has in development.

The company does not have the cash to acquire a fair dinkum asset that can stand on the same level as the current drugs, IMO. Not to mention, the cash should be used to clinically progress the existing assets.

Combine that with the PR firm and Jazzy Joel going on patrol in the US, and I think that this is more likely due to big names giving the IHL-42x results the attention it deserved.